Researchers have identified a way to alter how immune cells make a receptor for the hormone prolactin, reducing signs of autoimmune activity in laboratory samples and kidney damage in lupus-prone mice. The work offers a possible route toward more selective treatment, but it has not established a treatment for people with lupus.
The distinction matters. Some experiments used immune cells from people with systemic lupus erythematosus outside the body. The kidney result came from mice. Neither finding shows that a patient given the experimental molecule would improve, avoid side effects or be able to replace existing medicines.
The research paper, published November 2, 2026, in Experimental & Molecular Medicine, explores a question that sits between genetics and immunology: could changing the balance between two forms of the same receptor alter harmful immune responses while leaving more healthy cells intact?
Why lupus is difficult to treat selectively
Systemic lupus erythematosus, often called lupus or SLE, is an autoimmune disease in which the immune system mistakenly attacks the body’s own tissues. It can affect different organs and people in different ways. Inflammation involving the kidneys is one serious complication, although not every person with lupus has the same pattern of disease.
The immune system is not a single switch. It contains many interacting cell populations that protect against infections, remove damaged material and coordinate responses. In lupus, some of those processes become misdirected. Treatments that dampen immune activity can be essential, but targeting harmful activity while preserving protective functions is a difficult design problem.
That is the motivation behind this study. The researchers were not simply asking whether immune activity could be reduced. They were asking whether an abnormal feature of disease-associated cells might provide a more selective point of intervention.
One receptor, two forms
Prolactin is a signaling hormone with roles in multiple tissues. Cells respond to it through prolactin receptors. As the University of California, Riverside explains, the receptor can occur in long and short forms. Both have the same hormone-binding region outside the cell, but differ in how they signal inside it.
The researchers found that immune cells in lupus samples had a higher ratio of the long form to the short form than the comparison samples. The long form itself is not a new mutation or inherently abnormal. The question is whether the balance between forms changes the behavior of particular cells in the context of disease.
This is an important difference from saying that prolactin alone causes lupus. A disease may involve multiple interacting factors, and this paper investigates one signaling mechanism. The findings also do not establish that measuring a person’s prolactin level is enough to diagnose lupus or determine the right treatment.
What does RNA splicing have to do with it?
Genes provide instructions for making proteins, but the first RNA copy of a gene is processed before it is used. Splicing is one part of that processing. By including or excluding particular sections, a cell can produce different versions of a protein from instructions associated with the same gene.
The team used short synthetic molecules called splice-modulating oligomers. These were designed to interfere with the production of the long receptor form while shifting the balance toward short forms. This is a more precise description than saying the molecules turn off the hormone or remove every prolactin receptor from the body.
The receptor’s two forms share their external binding region, so an approach acting on RNA processing may offer a different way to distinguish them. Whether that theoretical advantage can be preserved safely in people remains a separate question. Precision in a laboratory design does not automatically mean precision in every tissue of a living person.
What did the experiments find?
The paper describes analyses of human immune-cell samples, including cells from people with lupus and healthy donors, and experiments in lupus-prone mice. The researchers used methods including RNA sequencing and analysis of immune-cell populations to examine receptor forms and inflammatory signals.
In their human sample experiments, shifting receptor expression was associated with reductions in disease-linked immune characteristics. The researchers also reported reductions in certain inflammatory signaling measures. These are biological observations from samples studied outside the body; they are not measurements of symptom relief in patients.
In the mice, the intervention reduced features of autoimmune activity and prevented the kidney pathology measured in the models. The kidney’s filtering structures are called glomeruli, and damage to them can be important in lupus. The observed mouse result makes the question worth investigating further, but it does not prove the same effect in human kidneys.
The researchers reported that the intervention reduced harmful immune-cell subsets without negative effects on healthy donor counterparts in the experiments they described. That is encouraging as a laboratory observation. It is not the same as demonstrating that healthy immune function is preserved in patients over months or years.
Why a mouse model is a starting point
A mouse model allows researchers to study immune activity and organ effects within a living system. It can show interactions that isolated cells cannot. However, mice are not miniature versions of patients, and laboratory models capture only some features of a varied human disease.
A candidate that looks selective in one experimental setting may distribute differently through human tissues, require a different dose or produce unexpected effects over time. The patients who might eventually receive such a therapy would also differ in age, disease activity, organ involvement and other treatments.
Human cell samples add a valuable connection to the disease, but they cannot answer all those questions either. Cells outside the body no longer experience the full environment of circulating hormones, organs and immune responses. The most informative interpretation combines both types of evidence while respecting their limits.
What would need to happen before patients could use it?
The research team says the approach remains preclinical. Further testing would need to establish how the molecule moves through the body, whether it reaches relevant cells, what dose is appropriate and which unwanted effects might arise. Manufacturing and quality controls would also have to meet standards appropriate for clinical development.
Only after the necessary preclinical and regulatory steps could researchers evaluate an appropriate candidate in human trials. Early trials generally have different goals from later trials, and there is no assurance that a promising laboratory strategy will become an approved medicine.
The university reports that it holds a patent related to the receptor-targeting molecule and that a follow-on application is pending. That context is relevant when interpreting enthusiasm for development, alongside the published methods and the need for independent replication.
What this means for someone living with lupus
The finding offers a clear scientific idea: changing the relative production of two receptor forms may alter pathways involved in autoimmune activity. It does not show that people should seek an unapproved compound, change their medication or alter hormone levels.
Lupus management is individualized, especially when organs such as the kidneys are involved. Anyone with questions about their own diagnosis or treatment should discuss them with their treating clinician. The next meaningful milestones for this research are additional validation, safety work and, if justified, carefully designed human studies.
Explore the book: How to Do Hard Things: The Discomfort Trap
Comments are closed.